A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ONCY SEC filings page.
This page shows Oncolytics Biotech, Inc. (ONCY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business converts most operating losses into cash use, but shrinking assets and rising liabilities pushed FY2025 equity below zero.
In FY2025, operating cash flow was-$20.1M against a net loss of$28.8M , so accounting losses largely translated into cash consumption. Free cash flow was-$20.1M , nearly identical to operating cash flow, indicating minimal cash reinvestment beyond operations.
Assets fell
SG&A rose
Financial Health Signals
We do not publish a peer-relative financial health score for Oncolytics Biotech, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Oncolytics Biotech, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Oncolytics Biotech, Inc. reported a net loss of $28.8M while operations used $20.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Oncolytics Biotech, Inc.'s EBITDA was -$9.7M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Oncolytics Biotech, Inc. reported a net loss of $9.7M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Oncolytics Biotech, Inc. earned -$0.08 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
Oncolytics Biotech, Inc. recorded an outflow of $6.9M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Oncolytics Biotech, Inc. held $2.4M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
None of these metrics is reported for Q3 2026.
Capital Allocation
Oncolytics Biotech, Inc. invested $5.2M in research and development in Q3 2026. This represents an increase of 1.4% from the same quarter a year earlier. Against the prior quarter it is up 20.9%.
Oncolytics Biotech, Inc. invested $7K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 75.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
ONCY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $5.2M+1.4% | $4.3M+122.4% | $4.6M+62.6% | $3.5M | $5.1M | $1.9M | $2.8M | N/A |
| SG&A Expenses | $4.6M+2.4% | $5.1M+87.1% | $4.7M+112.9% | $6.0M | $4.5M | $2.7M | $2.2M | N/A |
| Operating Income | -$9.7Mn/m | -$9.4Mn/m | -$9.3Mn/m | -$9.5M | -$9.6M | -$4.7M | -$5.0M | N/A |
| EBITDA | -$9.7Mn/m | -$9.4Mn/m | -$9.3Mn/m | -$9.5M | -$9.5M | -$4.6M | -$5.0M | N/A |
| Income Tax | -$13Kn/m | $101K+65.6% | N/A | N/A | -$181K | $61K | N/A | N/A |
| Net Income | -$9.7Mn/m | -$9.4Mn/m | -$9.2Mn/m | -$8.9M | -$9.9M | -$5.3M | -$4.7M | N/A |
| EPS (Basic) | -$0.08n/m | -$0.08n/m | -$0.08n/m | N/A | -$0.10 | -$0.06 | -$0.06 | N/A |
| EPS (Diluted) | -$0.08n/m | -$0.08n/m | -$0.08n/m | N/A | -$0.10 | -$0.06 | -$0.06 | N/A |
| Diluted Shares (Avg) | 128M+26.2% | 120M+31.6% | 112M+32.7% | N/A | 101M | 91M | 85M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
ONCY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.8M | $7.7M | $8.2M | $7.6M-43.5% | N/A | N/A | N/A | $13.4M |
| Current Assets | $5.3M | $7.1M | $7.5M | $6.8M-45.0% | N/A | N/A | N/A | $12.4M |
| Cash & Equivalents | $2.4M-72.6% | $4.1M-61.6% | $5.5M-48.4% | $5.2M-53.0% | $8.9M | $10.7M | $10.6M | $11.1M |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0 | $0 | $0 |
| Total Liabilities | $13.3M | $13.8M | $13.3M | $11.4M+12.4% | N/A | N/A | N/A | $10.1M |
| Current Liabilities | $5.9M | $5.2M | $5.4M | $6.1M+24.9% | N/A | N/A | N/A | $4.9M |
| Non-Current Liabilities | $7.4M | $8.6M | $7.9M | $5.3M+0.8% | N/A | N/A | N/A | $5.2M |
| Total Equity | -$7.5Mn/m | -$6.2M-266.7% | -$5.1M-237.7% | -$3.8M-215.2% | -$272K | $3.7M | $3.7M | $3.3M |
| Retained Earnings | -$457.9M | -$448.2M | -$438.7M | -$429.5Mn/m | N/A | N/A | N/A | -$400.7M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ONCY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.9Mn/m | -$8.1Mn/m | -$7.3Mn/m | -$6.4M | -$4.8M | -$4.1M | -$4.7M | N/A |
| Depreciation & Amortization | $17K0.0% | $15K-16.7% | $16K-15.8% | $16K | $17K | $18K | $19K | N/A |
| Stock-Based Compensation | $2.0M-21.2% | $2.4M+575.4% | $2.3M+172.1% | N/A | $2.6M | $362K | $845K | N/A |
| Capital Expenditures | $7K+75.0% | $0n/m | $6K+500.0% | $1K | $4K | $0 | $1K | N/A |
| Free Cash Flow | -$6.9Mn/m | -$8.1Mn/m | -$7.3Mn/m | -$6.4M | -$4.8M | -$4.1M | -$4.7M | N/A |
| Investing Cash Flow | -$7Kn/m | $0n/m | -$6Kn/m | -$1K | -$4K | $0 | -$1K | N/A |
| Financing Cash Flow | $5.2M+69.7% | $6.8M+65.4% | $7.6M+82.0% | $2.8M | $3.1M | $4.1M | $4.2M | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ONCY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$3.8M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Oncolytics Biotech, Inc. ONCY | FY2025 | N/A | -$28.8M | N/A | $47.7M | — |
| Verrica Pharmaceuticals Inc. VRCA | FY2025 | $35.6M | -$17.9M | -50.3% | $47.1M | 66/100 |
| RenovoRx, Inc. RNXT | FY2025 | $1.1M | -$11.2M | N/A | $45.5M | 57/100 |
| Annovis Bio, Inc. ANVS | FY2025 | $0 | -$28.9M | N/A | $44.1M | — |
| Acrivon Therapeutics, Inc. ACRV | FY2025 | N/A | -$77.9M | N/A | $49.3M | — |
| ImageneBio, Inc. IMA | FY2025 | $800K | -$45.3M | N/A | $48.8M | — |
Where Oncolytics Biotech, Inc. Ranks
Frequently Asked Questions
No, Oncolytics Biotech, Inc. (ONCY) reported a net loss of $37.3M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $28.8M.
Oncolytics Biotech, Inc. (ONCY) had EBITDA of -$28.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Oncolytics Biotech, Inc. (ONCY) recorded an outflow of $20.1M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Oncolytics Biotech, Inc. (ONCY) recorded an outflow of $20.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Oncolytics Biotech, Inc. (ONCY) had $7.6M in total assets as of fiscal year 2025, including both current and long-term assets.
Oncolytics Biotech, Inc. (ONCY) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Oncolytics Biotech, Inc. (ONCY) invested $13.3M in research and development during fiscal year 2025.
Oncolytics Biotech, Inc. (ONCY) had a current ratio of 1.12 as of fiscal year 2025, which is considered adequate.
Oncolytics Biotech, Inc. (ONCY) had a return on assets of -379.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Oncolytics Biotech, Inc. (ONCY) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $47.7M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Oncolytics Biotech, Inc. (ONCY) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $47.7M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Oncolytics Biotech, Inc. (ONCY) held $5.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $20.1M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Oncolytics Biotech, Inc. (ONCY) has negative shareholder equity of -$3.8M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Oncolytics Biotech, Inc. (ONCY) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Oncolytics Biotech, Inc. (ONCY) reported a net loss of $28.8M while operations used $20.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.